-
08
2022
Caliway Announces Achievements in Revolutionary Fat Reduction Therapy
CBL-514 has demonstrated promising clinical effectiveness and safety in reducing local fat through a mechanism of adipocytes apoptosis.
-
04
2022
FDA grants IND approval for phase II for treating rare diseases
CBL-514 injection is suitable for treating rare diseases- Dercum's disease. Applications for U.S. Phase II IND was approved. Upcoming IPO in 2022.
